Gemzar (gemcitabine)

Phase 3UNKNOWN
0 watching 0 views this weekπŸ“ˆ Rising
77
Hype Score

Development Stage

βœ“
Pre-clinical
βœ“
Phase 1
βœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cervical Cancer

Conditions

Cervical Cancer

Trial Timeline

Feb 1, 2009 β†’ Jan 1, 2013

About Gemzar (gemcitabine)

Gemzar (gemcitabine) is a phase 3 stage product being developed by Eli Lilly for Cervical Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT00842660. Target conditions include Cervical Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00842660Phase 3UNKNOWN

Competing Products

20 competing products in Cervical Cancer

See all competitors
ProductCompanyStageHype Score
PRGN-2009 plus Pembrolizumab + Pembrolizumab alonePrecigenPhase 2
47
ABP-450AEON BiopharmaPhase 2
44
ABP-450 + PlaceboAEON BiopharmaPhase 2
44
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Sacituzumab tirumotecan plus IparomlimabSun PharmaceuticalPhase 2
52
Amolimogene + AmolimogeneEisaiPhase 2/3
65
BOTULINUM TOXIN TYPE BEisaiPhase 2
52
PemetrexedEli LillyPhase 2
52
SHR-A1811 InjectionJiangsu Hengrui MedicinePhase 2
52
camrelizumabοΌ› famitinib malate + platinum-based chemotherapyJiangsu Hengrui MedicinePhase 3
77
SHR-1210 + SHR-1020 + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Cisplatin or CarboplatinJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Cisplatin or CarboplatinJiangsu Hengrui MedicinePhase 2
52
Volrustomig + Cisplatin + Carboplatin + PaclitaxelAstraZenecaPhase 2
52
VolrustomigAstraZenecaPhase 3
77
Durvalumab + Cisplatin + CarboplatinAstraZenecaPhase 3
77
VolrustomigAstraZenecaPhase 2
52
PembrolizumabMerckPhase 2
52